News

EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...
Morningstar11d
VANI - Vivani Medical Inc Trailing Returns | Morningstar
Stay up to date on how Vivani Medical Inc (VANI:XNAS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.
PipelineReview.com3d
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and ...
LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...
Yahoo Finance4d
Vivani Medical, Inc. (VANI) - Yahoo Finance
Find the latest Vivani Medical, Inc. (VANI) stock quote, history, news and other vital information to help you with your stock trading and investing.